Klotho Neurosciences (KLTO)announced that it had received a notification letter from Nasdaq confirming that the company has regained compliance with the minimum $1.00 bid price under Nasdaq Listing Rule 5550(a)(2), and the minimum stockholders’ equity threshold of $2.5M under Listing Rule 5550(b)(1). The company is now in full compliance with all Nasdaq continued listing requirements and will remain listed and traded on Nasdaq.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLTO:
- Klotho Neurosciences Receives FDA Orphan Drug Designation
- Klotho Neurosciences granted Orphan Drug Designation for KLTO-202
- Klotho Neurosciences amyotrophic lateral sclerosis treatment gets orphan status
- 3 Penny Stocks to Watch Now, 7/1/25
- Klotho Neurosciences Begins Manufacturing Gene Therapy for ALS